
THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION

No. 459 Session of
2019

INTRODUCED BY STRUZZI, JOZWIAK, PASHINSKI, PICKETT AND
SCHLOSSBERG, SEPTEMBER 3, 2019

REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 3, 2019

A RESOLUTION

1 Urging the United States Food and Drug Administration to
2 promptly consider guidelines and protocols for the approval
3 of cannabidiol as a product which is legally available for
4 resale.

5 WHEREAS, The United States is seeing a change in the use of
6 marijuana for medical purposes; and

7 WHEREAS, Thirty-three states and the District of Columbia
8 have recognized that marijuana may have medical purposes; and

9 WHEREAS, This Commonwealth is one of the states which has
10 legalized the use of medical marijuana for limited purposes,
11 including serious medical conditions; and

12 WHEREAS, Under Federal law, the 2018 Farm Bill has created
13 additional questions with respect to the definition of marihuana
14 in Schedule I of the Controlled Substances Act; and

15 WHEREAS, Cannabidiol (CBD) is a product which can be derived
16 from a variety of marijuana plants, including, industrial hemp;
17 and

18 WHEREAS, The Federal Government has removed hemp and all
19 parts of the plant from the definition of marihuana in Schedule

1 I of the Controlled Substances Act; and

2 WHEREAS, The United States Food and Drug Administration (FDA)
3 has previously approved epidiolex as a medicine which contains
4 CBD; and

5 WHEREAS, It is unclear whether or not the FDA regulates
6 commercially available CBD; and

7 WHEREAS, It is in the interest of public safety to have a
8 streamlined and consistent oversight system for CBD and CBD
9 products; therefore be it

10 RESOLVED, That the House of Representatives of the
11 Commonwealth of Pennsylvania urge the United States Food and
12 Drug Administration to promptly consider guidelines and
13 protocols for approval of cannabidiol as a product which is
14 legally available for resale; and be it further

15 RESOLVED, That a copy of this resolution be transmitted to
16 the headquarters of the United States Food and Drug
17 Administration at 10903 New Hampshire Avenue, Silver Spring,
18 Maryland 20993.